라이브 바이오테라퓨틱스 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 용도별, 제품 유형별, 사업 규모별, 지역별, 경쟁별(2020-2030년)
Live Biotherapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Product, By Type of Formulation, By Scale of Operation, By Region and Competition, 2020-2030F
상품코드:1770881
리서치사:TechSci Research
발행일:2025년 07월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
라이브 바이오테라퓨틱스 세계 시장은 2024년에는 1억 1,234만 달러로 평가되었으며, 2030년에는 2억 4,769만 달러에 달하고, CAGR 14.06%로 성장할 것으로 예측됩니다.
제약회사와 생명공학 기업들이 만성질환과 감염성 질환을 치료하기 위해 미생물 기반 치료법에 대한 투자를 늘리면서 시장이 크게 성장하고 있습니다. 질병을 치료하거나 예방하기 위해 살아있는 미생물을 포함하는 생물학적 제품으로 정의되는 살아있는 바이오 치료 제품(LBP)은 소화기 질환, 대사성 질환, 암과 같은 증상에서 유망한 용도를 보이고 있습니다. 장내 미생물이 인체 건강에 미치는 역할에 대한 과학적 이해도가 높아짐에 따라 연구기관과 투자자들의 관심도 높아지고 있습니다. 또한, 미국 FDA와 유럽의약품청(European Medicines Agency)과 같은 규제 기관은 LBP 개발에 대한 구체적인 가이드라인을 도입하여 정당성을 높이고 이 분야에 대한 혁신과 투자를 촉진하고 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
1억 1,234만 달러
시장 규모 : 2030년
2억 4,769만 달러
CAGR : 2025-2030년
14.06%
급성장 부문
임상 스케일 오퍼레이션
최대 시장
북미
시장 촉진요인
만성질환 증가
주요 시장 과제
규제 불확실성과 가이드라인의 진화
주요 시장 동향
미생물 기반 치료제에 대한 관심 증가
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 라이브 바이오테라퓨틱스 시장 전망
시장 규모 및 예측
금액별
시장 점유율과 예측
용도별(클로스트리듐 디피실, 크론병, 과민성대장증후군, 당뇨병, 기타)
제품별(API, FDF)
제제 종류별(고형 제제, 경구 액제, 주사제, 기타)
사업 규모별(전임상 규모 사업, 임상 규모 사업, 상업 규모 사업)
기업별(2024)
지역별
시장 맵
제6장 북미의 라이브 바이오테라퓨틱스 시장 전망
시장 규모 및 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
멕시코
캐나다
제7장 유럽의 라이브 바이오테라퓨틱스 시장 전망
시장 규모 및 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 라이브 바이오테라퓨틱스 시장 전망
시장 규모 및 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
한국
일본
호주
제9장 남미의 라이브 바이오테라퓨틱스 시장 전망
시장 규모 및 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 라이브 바이오테라퓨틱스 시장 전망
시장 규모 및 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병
제품 출시
최근 동향
제13장 혼란 : 분쟁, 팬데믹, 무역장벽
제14장 Porter's Five Forces 분석
업계내 경쟁
신규 참여의 가능성
공급업체의 능력
고객의 능력
대체품의 위협
제15장 경쟁 구도
Arrant Bio
4D Pharma
Cerbios
Biose Industrie
Assembly Biosciences, Inc.
Wacker Chemie AG
Quay Pharmaceuticals
NIZO
Lonza
Inpac Probiotics
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
ksm
영문 목차
영문목차
The Global Live Biotherapeutics Market was valued at USD 112.34 Million in 2024 and is expected to reach USD 247.69 Million by 2030, growing at a CAGR of 14.06%. The market is witnessing strong growth as pharmaceutical and biotech companies increasingly invest in microbiome-based therapies to address chronic and infectious diseases. Live biotherapeutic products (LBPs)-defined as biological products containing live microorganisms for disease treatment or prevention-are showing promising applications in conditions like gastrointestinal disorders, metabolic diseases, and cancer. As scientific understanding of the gut microbiome's role in human health advances, research institutions and investors are showing increased interest. Additionally, regulatory agencies such as the U.S. FDA and the European Medicines Agency are introducing specific guidelines for LBP development, providing greater legitimacy and encouraging further innovation and investment in the field.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 112.34 Million
Market Size 2030
USD 247.69 Million
CAGR 2025-2030
14.06%
Fastest Growing Segment
Clinical Scale Operations
Largest Market
North America
Key Market Drivers
Increasing Prevalence of Chronic Diseases
The rising global burden of chronic diseases is a major driver fueling the growth of the Live Biotherapeutics Market. Chronic conditions such as cardiovascular diseases, cancer, and diabetes are becoming more widespread due to risk factors like poor diet, alcohol use, smoking, and sedentary lifestyles. According to a 2019 report by the Pan American Health Organization (PAHO), ischemic heart disease caused 73.6 deaths per 100,000 population globally, followed by stroke (32.3), other circulatory diseases (14.8), hypertensive heart disease (10.6), and cancer as a leading secondary contributor to mortality. As these chronic diseases persist and increase in incidence, there is a growing need for innovative therapies that can address underlying causes and improve long-term outcomes. Live biotherapeutic products, by modulating the microbiome, offer potential as adjunct or standalone treatments in these chronic health areas, driving continued market expansion.
Key Market Challenges
Regulatory Uncertainty and Evolving Guidelines
One of the primary obstacles facing the Global Live Biotherapeutics Market is the ongoing uncertainty surrounding regulatory frameworks. Live biotherapeutic products involve complex and diverse microbial compositions that challenge traditional regulatory classifications. Agencies like the FDA and EMA are actively developing new guidelines, but the evolving nature of these regulations creates challenges for companies in terms of compliance, product approval, and commercialization timelines. This fluid regulatory environment can lead to increased development costs, extended approval periods, and complex multi-region compliance requirements. Moreover, the lack of harmonization across global regulatory bodies further complicates market entry, particularly for firms aiming to launch products internationally. Companies must constantly adapt to changing requirements, which demands significant time, financial resources, and regulatory expertise-slowing market penetration and increasing operational burden.
Key Market Trends
Rising Interest in Microbiome-Based Therapeutics
The increasing focus on microbiome-based therapeutics is shaping the trajectory of the Global Live Biotherapeutics Market. Scientific discoveries highlighting the microbiome's role in regulating immunity, digestion, metabolism, and disease resistance have positioned it as a key target for drug development. Pharmaceutical and biotech firms are increasingly leveraging this understanding to create targeted therapies that restore microbiome balance, particularly in diseases such as inflammatory bowel disease (IBD), cancer, and autoimmune conditions. As research continues to demonstrate the therapeutic relevance of microbiota modulation, demand for live biotherapeutic products is expanding. This trend is also attracting investment from both public and private sectors, leading to greater innovation and pipeline growth within the LBP segment.
Key Market Players
Arrant Bio
4D Pharma
Cerbios
Biose Industrie
Assembly Biosciences, Inc.
Wacker Chemie AG
Quay Pharmaceuticals
NIZO
Lonza
Inpac Probiotics
Report Scope:
In this report, the Global Live Biotherapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Live Biotherapeutics Market, By Application:
C. difficile
Crohn's Disease
IBS
Diabetes
Others
Live Biotherapeutics Market, By Product:
APIs
FDFs
Live Biotherapeutics Market, By Type of Formulation:
Solid Formulations
Oral Liquids
Injectables
Others
Live Biotherapeutics Market, By Scale of Operation:
Preclinical Scale Operations
Clinical Scale Operations
Commercial Scale Operations
Live Biotherapeutics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Live Biotherapeutics Market.
Available Customizations:
Global Live Biotherapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global Live Biotherapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Application (C.difficle, Crohns disease, IBS, Diabetes, Others)
5.2.2. By Product (APIs, FDFs)
5.2.3. By Type of Formulation (Solid Formulations, Oral Liquids, Injectables, Others)
5.2.4. By Scale of Operation (Preclinical Scale Operations, Clinical Scale Operations, Commercial Scale Operations)
5.2.5. By Company (2024)
5.2.6. By Region
5.3. Market Map
6. North America Live Biotherapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Application
6.2.2. By Product
6.2.3. By Type of Formulation
6.2.4. By Scale of Operation
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Live Biotherapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Application
6.3.1.2.2. By Product
6.3.1.2.3. By Type of Formulation
6.3.1.2.4. By Scale of Operation
6.3.2. Mexico Live Biotherapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Application
6.3.2.2.2. By Product
6.3.2.2.3. By Type of Formulation
6.3.2.2.4. By Scale of Operation
6.3.3. Canada Live Biotherapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Application
6.3.3.2.2. By Product
6.3.3.2.3. By Type of Formulation
6.3.3.2.4. By Scale of Operation
7. Europe Live Biotherapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Application
7.2.2. By Product
7.2.3. By Type of Formulation
7.2.4. By Scale of Operation
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. France Live Biotherapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Application
7.3.1.2.2. By Product
7.3.1.2.3. By Type of Formulation
7.3.1.2.4. By Scale of Operation
7.3.2. Germany Live Biotherapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Application
7.3.2.2.2. By Product
7.3.2.2.3. By Type of Formulation
7.3.2.2.4. By Scale of Operation
7.3.3. United Kingdom Live Biotherapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Application
7.3.3.2.2. By Product
7.3.3.2.3. By Type of Formulation
7.3.3.2.4. By Scale of Operation
7.3.4. Italy Live Biotherapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Application
7.3.4.2.2. By Product
7.3.4.2.3. By Type of Formulation
7.3.4.2.4. By Scale of Operation
7.3.5. Spain Live Biotherapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Application
7.3.5.2.2. By Product
7.3.5.2.3. By Type of Formulation
7.3.5.2.4. By Scale of Operation
8. Asia-Pacific Live Biotherapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Application
8.2.2. By Product
8.2.3. By Type of Formulation
8.2.4. By Scale of Operation
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Live Biotherapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Application
8.3.1.2.2. By Product
8.3.1.2.3. By Type of Formulation
8.3.1.2.4. By Scale of Operation
8.3.2. India Live Biotherapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Application
8.3.2.2.2. By Product
8.3.2.2.3. By Type of Formulation
8.3.2.2.4. By Scale of Operation
8.3.3. South Korea Live Biotherapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Application
8.3.3.2.2. By Product
8.3.3.2.3. By Type of Formulation
8.3.3.2.4. By Scale of Operation
8.3.4. Japan Live Biotherapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Application
8.3.4.2.2. By Product
8.3.4.2.3. By Type of Formulation
8.3.4.2.4. By Scale of Operation
8.3.5. Australia Live Biotherapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Application
8.3.5.2.2. By Product
8.3.5.2.3. By Type of Formulation
8.3.5.2.4. By Scale of Operation
9. South America Live Biotherapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Application
9.2.2. By Product
9.2.3. By Type of Formulation
9.2.4. By Scale of Operation
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Live Biotherapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Application
9.3.1.2.2. By Product
9.3.1.2.3. By Type of Formulation
9.3.1.2.4. By Scale of Operation
9.3.2. Argentina Live Biotherapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Application
9.3.2.2.2. By Product
9.3.2.2.3. By Type of Formulation
9.3.2.2.4. By Scale of Operation
9.3.3. Colombia Live Biotherapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Application
9.3.3.2.2. By Product
9.3.3.2.3. By Type of Formulation
9.3.3.2.4. By Scale of Operation
10. Middle East and Africa Live Biotherapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Application
10.2.2. By Product
10.2.3. By Type of Formulation
10.2.4. By Scale of Operation
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Live Biotherapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Application
10.3.1.2.2. By Product
10.3.1.2.3. By Type of Formulation
10.3.1.2.4. By Scale of Operation
10.3.2. Saudi Arabia Live Biotherapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Application
10.3.2.2.2. By Product
10.3.2.2.3. By Type of Formulation
10.3.2.2.4. By Scale of Operation
10.3.3. UAE Live Biotherapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Application
10.3.3.2.2. By Product
10.3.3.2.3. By Type of Formulation
10.3.3.2.4. By Scale of Operation
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Disruptions: Conflicts, Pandemics and Trade Barriers
